Another Roche MAGE-A4 trial disappears, withdrawn without enrolling after strategic review

Roche has made another MAGE-A4 program disappear, withdrawing a phase 1 trial of a T-cell bispecific prospect before a single patient was enrolled.

The withdrawal, which ApexOnco reported earlier this week, followed a series of delays to the start date of the trial. Roche’s Genentech unit had planned to start testing the MAGE-A4xCD3 bispecific in solid tumor patients in July but pushed the date back over the summer.